计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G610702-1mg |
1mg |
期货 ![]() |
| |
| G610702-5mg |
5mg |
期货 ![]() |
| |
| G610702-10mg |
10mg |
期货 ![]() |
| |
| G610702-25mg |
25mg |
期货 ![]() |
| |
| G610702-50mg |
50mg |
期货 ![]() |
|
| 别名 | GSK-2256294 | GSK-2256294A | GSK2256294A |
|---|---|
| 英文别名 | GSK-2256294A | GSK-2256294 | GSK2256294A | cis-N-((4-Cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | GSK2256294 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 环氧化物氢化酶抑制剂 |
| 产品介绍 |
GSK2256294A (GSK 2256294) 是一种选择性的,以及口服活性的 soluble epoxide hydrolase (sEH) 抑制剂。GSK2256294A 对人的重组 sEH、大鼠同源 sEH 和小鼠同源 sEH 具有抑制作用,其 IC50 值分别为 27、61 和 189 pM。GSK2256294A 可用于慢性阻塞性肺疾病 (COPD) 和心血管疾病的研究。
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease
|
| 纯度 | ≥98% |
| ALogP | 3.7 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (1R,3S)-N-[[4-cyano-2-(trifluoromethyl)phenyl]methyl]-3-[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]cyclohexane-1-carboxamide |
| INCHI | 1S/C21H24F3N7O/c1-12-28-19(26-2)31-20(29-12)30-16-5-3-4-14(9-16)18(32)27-11-15-7-6-13(10-25)8-17(15)21(22,23)24/h6-8,14,16H,3-5,9,11H2,1-2H3,(H,27,32)(H2,26,28,29,30,31)/t14-,16+/m1/s1 |
| InChi Key | LQHDJQIMETZMPH-ZBFHGGJFSA-N |
| Smiles | CC1=NC(=NC(=N1)NC2CCCC(C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)NC |
| Isomeric SMILES | CC1=NC(=NC(=N1)N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)NC |
| PubChem CID | 59448236 |
| 分子量 | 447.46 |
| 溶解性 | DMSO: 45 mg/mL (100.57 mM) |
|---|---|
| 分子量 | 447.500 g/mol |
| XLogP3 | 3.700 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 447.199 Da |
| 单同位素质量Monoisotopic Mass | 447.199 Da |
| 拓扑极表面积Topological Polar Surface Area | 116.000 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 682.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
¥2,420.90
| 1. Spector AA, Norris AW. (2007) Action of epoxyeicosatrienoic acids on cellular function.. Am J Physiol, Cell Physiol, 292 (3): (C996-1012). [PMID:16987999] |
| 2. Spector AA, Fang X, Snyder GD, Weintraub NL. (2004) Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.. Prog Lipid Res, 43 (1): (55-90). [PMID:14636671] |
| 3. Lazaar AL, Yang L, Boardley RL, Goyal NS, Robertson J, Baldwin SJ, Newby DE, Wilkinson IB, Tal-Singer R, Mayer RJ et al.. (2016) Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.. Br J Clin Pharmacol, 81 (5): (971-9). [PMID:26620151] |